Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 5, 2014, Pages 432-437

  Camargo, L M ^a   Franc, C N ^a   Izar, M C ^a   Bianco, H T ^a   Lins, L S ^a   Barbosa, S P ^a   Pinheiro, L F ^a   Fonseca, F A H ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endothelial microparticles; Endothelial progenitor cells; Platelet aggregation; Platelet microparticles; Simvastatin ezetimibe

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; ASPIRINA PREVENT; CLOPIDOGREL; CREATINE KINASE; CREATININE; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLAGREL; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; DRUG COMBINATION; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MALE; MIDDLE AGED; PLATELET MICROPARTICLE; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CORONARY DISEASE; DRUG COMBINATION; DRUG EFFECTS; MEMBRANE MICROPARTICLE;

AGED; ANTICHOLESTEREMIC AGENTS; ASPIRIN; AZETIDINES; CELL-DERIVED MICROPARTICLES; CHOLESTEROL, LDL; CORONARY DISEASE; DRUG COMBINATIONS; ENDOTHELIAL PROGENITOR CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SIMVASTATIN; TICLOPIDINE; TRIGLYCERIDES;

EID: 84899996467     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143628     Document Type: Article

References (32)

1. Sung SH, Wu TC, Chen JS, Chen YH, Huang PH, Lin SJ, et al. Reduced number and impaired function of circulating endothelial progenitor cells in patients with abdominal aortic aneurysm. Int J Cardiol 2013; 168: 1070-1077. doi: 10.1016/j.ijcard.2012.11.002.
2. Mueller C, Wodack K, Twelker K, Werner N, Custodis F, Nickenig G. Darbepoetin improves endothelial function and increases circulating endothelial progenitor cell number in patients with coronary artery disease. Heart 2011; 97: 1474-1478. doi: 10.1136/hrt.2010.220798.
3. da Silva EF, Fonseca FA, Franca CN, Ferreira PR, Izar MC, Salomao R, et al. Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. AIDS 2011; 25: 1595-1601. doi: 10.1097/QAD.0b013e32834980f4.
4. Feng B, Chen Y, Luo Y, Chen M, Li X, Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 2010; 208: 264-269. doi: 10.1016/j.atherosclerosis.2009.06.037.
5. Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, et al. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 2010; 28: 1655-1665. doi: 10.1097/HJH.0b013e32833a4d0a.
6. Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 112-116. doi: 10.1161/01.ATV.0000191634.13057.15.
7. Cesari F, Marcucci R, Gori AM, Burgisser C, Francini S, Sofi F, et al. Impact of a cardiac rehabilitation program and inflammatory state on endothelial progenitor cells in acute coronary syndrome patients. Int J Cardiol 2013; 167: 1854-1859. doi: 10.1016/j.ijcard.2012.04.157.
8. Chen J, Jin J, Song M, Dong H, Zhao G, Huang L. C-reactive protein down-regulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor for advanced glycation end-products. Gene 2012; 496: 128-135. doi: 10.1016/j.gene.2011.12.039.
9. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15: 467-478. doi: 10.2174/138161209787315684.
10. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010; 74: 818-826. doi: 10.1253/circj.CJ-10-0110.
11. Pinheiro LF, Franca CN, Izar MC, Barbosa SP, Bianco HT, Kasmas SH, et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int J Cardiol 2012; 158: 125-129. doi: 10.1016/j.ijcard.2012.04.051.
12. Franca CN, Pinheiro LF, Izar MC, Brunialti MK, Salomao R, Bianco HT, et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 2012; 76: 729-736. doi: 10.1253/circj.CJ-11-1145.
13. Choi DH, Choi JS, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. Pharmacol Rep 2011; 63: 1574-1582. doi: 10.1016/S1734-1140(11)70582-5.
14. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012; 11: 439-444. doi: 10.1517/14740338.2012.670633.
15. Diamant M, Tushuizen ME, Abid-Hussein MN, Hau CM, Boing AN, Sturk A, et al. Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost 2008; 100: 489-497.
16. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 2004; 18: 177-185. doi: 10.1007/s11239-005-0343-8.
17. Kasmas SH, Izar MC, Franca CN, Ramos SC, Moreira FT, Helfenstein T, et al. Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies. Braz J Med Biol Res 2012; 45: 1095-1101. doi: 10.1590/S0100- 879X2012007500118.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011; 300: H2-H12. doi: 10.1152/ajpheart.00471.2010.
20. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818. doi: 10.1093/eurheartj/ehr158.
21. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932. doi: 10.1093/eurheartj/ehr373.
22. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681. doi: 10.1016/S0140-6736(10)61350-5.
23. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590. doi: 10.1016/S0140-6736(12) 62027-3.
24. Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 2009; 43: 2012-2020. doi: 10.1345/aph.1M410.
25. Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med 2008; 359: 856-858. doi: 10.1056/NEJMe0805136.
26. Malmstrom RE, Settergren M, Bohm F, Pernow J, Hjemdahl P. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb Haemost 2009; 101: 157-164.
27. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370. doi: 10.2165/00003088- 200241050-00003.
28. Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 2012; 25: 348-356. doi: 10.1021/tx2004085.
29. Park Y, Jeong YH, Tantry US, Ahn JH, Kwon TJ, Park JR, et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J 2012; 33: 2151-2162. doi: 10.1093/eurheartj/ehs083.
30. Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, et al. Impact of cytochrome P450 3A4- metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99: 174-181.
31. Westerink J, Deanfield JE, Imholz BP, SpieringW, Basart DC, Coll B, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis 2013; 227: 118-124. doi: 10.1016/j.atherosclerosis.2012.11.028.
32. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-832. doi: 10.1016/j.ahj.2008.07.023.